Cystatin C: A potential target for Alzheimer's treatment

Expert Review of Neurotherapeutics

Volumn 8, Issue 5, 2008, Pages 687-689

  Levy, Efrat ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CYSTATIN C;

ALZHEIMER DISEASE; CELL AGGREGATION; DRUG BINDING; EDITORIAL; NERVE CELL DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; OLIGOMERIZATION; PLAQUE FORMING CELL;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; CYSTATINS; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, NEUROLOGICAL;

EID: 43249100084     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.5.687     Document Type: Editorial

References (22)

1. Bobek LA, Levine MJ. Cystatins - inhibitors of cysteine proteinases. Crit. Rev. Oral. Biol. Med. 3, 307-332 (1992).
2. Vinters HV, Nishimura GS, Secor DL, Pardridge WM. Immunoreactive A4 and γ-trace peptide colocalization in amyloidotic arteriolar lesions in brains of patients with Alzheimer's disease. Am. J. Pathol. 137, 233-240 (1990).
3. Maruyama K, Ikeda S, Ishihara T, Allsop D, Yanagisawa N. Immunohistochemical characterization of cerebrovascular amyloid in 46 autopsied cases using antibodies to β protein and cystatin C. Stroke 21, 397-403 (1990).
4. Itoh Y, Yamada M, Hayakawa M, Otomo E, Miyatake T. Cerebral amyloid angiopathy: a significant cause of cerebellar as well as lobar cerebral hemorrhage in the elderly. J. Neurol. Sci. 116, 135-141 (1993).
5. Haan J, Maat-Schieman MLC, van Duinen SG, Jensson O, Thorsteinsson L, Roos RAC. Co-localization of β/A4 and cystatin C in cortical blood vessels in Dutch, but not in Icelandic hereditary cerebral hemorrhage with amyloidosis. Acta Neurol. Scand. 89, 367-371 (1994).
6. Levy E, Sastre M, Kumar A et al. Codeposition of cystatin C with amyloid-β protein in the brain of Alzheimer's disease patients. J. Neuropathol. Exp. Neurol. 60, 94-104 (2001).
7. Wei L, Walker LC, Levy E. Cystatin C: Icelandic-like mutation in an animal model of cerebrovascular β amyloidosis. Stroke 27, 2080-2085 (1996).
8. Uchida K, Kuroki K, Yoshino T, Yamaguchi R, Tateyama S. Immunohistochemical study of constituents other than β-protein in canine senile plaques and cerebral amyloid angiopathy. Acta Neuropathol. (Berl.) 93, 277-284 (1997).
9. Steinhoff T, Moritz E, Wollmer MA, Mohajeri MH, Kins S, Nitsch RM. Increased cystatin C in astrocytes of transgenic mice expressing the K670N-M671L mutation of the amyloid precursor protein and deposition in brain amyloid plaques. Neurobiol. Dis. 8, 647-654 (2001).
10. Sastre M, Calero M, Pawlik M et al. Binding of cystatin C to Alzheimer's amyloid β inhibits amyloid fibril formation. Neurobiol. Aging 25, 1033-1043 (2004). •• Established for the first time the binding of amyloid-β (Aβ) to cystatin C and resultant inhibition of Aβ aggregation.
11. Pawlik M, Sastre M, Calero M et al. Overexpression of human cystatin C in transgenic mice does not affect levels of endogenous brain amyloid β peptide. J. Mol. Neurosci. 22, 13-18 (2004).
12. Bai Y, Markham K, Chen F et al. The in vivo brain interactome of the amyloid precursor protein. Mol. Cell. Proteomics 7, 15-34 (2008).
13. Selenica ML, Wang X, Ostergaard-Pedersen L, Westlind-Danielsson A, Grubb A. Cystatin C reduces the in vitro formation of soluble Aβ1-42 oligomers and protofibrils. Scand. J. Clin. Lab. Invest. 67, 179-190 (2007). •• Demonstrated that cystatin C decreases Aβ oligomerization.
14. Mi W, Pawlik M, Sastre M et al. Cystatin C inhibits amyloid-β deposition in Alzheimer's disease mouse models. Nat. Genet. 39, 1440-1442 (2007). •• Revealed the in vivo binding of soluble Aβ to cystatin C, resulting in inhibition of Aβ plaque formation in the brain of transgenic mice.
15. Kaeser SA, Herzig MC, Coomaraswamy J et al. Cystatin C modulates cerebral β-amyloidosis. Nat. Genet. 39, 1437-1439 (2007). •• Revealed the in vivo binding of soluble Aβ to cystatin C, resulting in inhibition of Aβ plaque formation in the brain of transgenic mice.
16. Madero M, Sarnak MJ, Stevens LA. Serum cystatin C as a marker of glomerular filtration rate. Curr. Opin. Nephrol. Hypertens. 15, 610-616 (2006).
17. Levy E, Jaskolski M, Grubb A. The role of cystatin C in cerebral amyloid angiopathy and stroke: cell biology and animal models. Brain Pathol. 16, 60-70 (2006).
18. Ghidoni R, Benussi L, Paterlini A et al. Presenilin 2 mutations alter cystatin C trafficking in mouse primary neurons. Neurobiol. Aging 28, 371-376 (2006).
19. Finckh U, von Der Kammer H, Velden J et al. Genetic association of a cystatin C gene polymorphism with late-onset Alzheimer disease. Arch. Neurol. 57, 1579-1583 (2000).
20. Benussi L, Ghidoni R, Steinhoff T et al. Alzheimer disease-associated cystatin C variant undergoes impaired secretion. Neurobiol. Dis. 13, 15-21 (2003).
21. Paraoan L, Ratnayaka A, Spiller DG, Hiscott P, White MR, Grierson I. Unexpected intracellular localization of the AMD-associated cystatin C variant. Traffic 5, 884-895 (2004).
22. Gene overview of all published AD association studies for CST3. www.alzforum.org/res/com/gen/alzgene/geneoverview.asp?geneid=66